2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Leukemia, Myeloid, Chronic-Phase
34
Leukemia
30
Leukemia, Myeloid, Acute
18
Breast Neoplasms
18
Recurrence
15
Prostatic Neoplasms
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Neoplasm Metastasis
12
Blast Crisis
12
Multiple Myeloma
11
Carcinoma, Non-Small-Cell Lung
11
Burkitt Lymphoma
11
Pancreatic Neoplasms
10
Neoplasms
9
Leukemia, Myeloid, Accelerated Phase
9
Lung Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
7
Glioblastoma
7
Melanoma
6
Lymphoma
6
Glioma
6
Rectal Neoplasms
5
Philadelphia Chromosome
5
Ovarian Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, Large B-Cell, Diffuse
5
Hematologic Neoplasms
5
Interventions
bicalutamide
5
enzalutamide
4
exemestane
2
darolutamide
2
abiraterone
2
pembrolizumab
1
ostarine
1
nilutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Prophylactic Mastectomy
1
Prednisolone
1
Panobinostat
1
Mifepristone
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
Dasatinib
×
Clear all
NCT00918385
2014-10-29
ARS
Duke University
Phase 2
Terminated
57 enrolled
8 charts